ChemoMetec A/S

About ChemoMetec A/S

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis in Denmark, the United States, Canada, rest of Europe, and internationally. The company offers automated cell counters and image analyzers, such as NucleoCounter NC-3000, an advanced image cytometer to characterize cell properties; NucleoCounter NC-250, an automated cell analyzer to characterize cell properties; NucleoCounter NC-202, a consistent cell counter; and NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination. It also provides NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension; NucleoCounter SP-100, a sperm cell counter that offers total sperm concentration and sperm viability in a semen sample from ejaculates or extended doses; and NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample. In addition, the company offers consumables comprising cassettes, reagents, slides, and test kits; and accessories, which include cables, power supplies, software, and labware products, as well as service plans. The company was founded in 1997 and is headquartered in Allerød, Denmark.

ChemoMetec is a worldwide leading manufacturer of automated cell counters and analysis equipment. Born in Scandinavia, operating globally.

CHEMM.CO Denmark

670.5USD0.5 (-0.07%)

• At close Thu Oct 06 2022

Copenhagen exchange

Sector: Technology

Industry: Scientific & Technical Instruments

Location Denmark, Allerød

Grade: ACA

1,080,085,979 USD
BETA (5y)


for 5 years
for 3 years
for 2 years
for last year
for this year
ChemoMetec A/S
© 2023 All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.